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Background: Based on improved clinical outcomes in randomized controlled clinical trials (RCTs) the FDA and EMA
have approved bevacizumab with interferon, sunitinib, and pazopanib in the first-line treatment of low to intermediate
risk metastatic clear cell renal cell carcinoma (mRCC). However, there is little comparative data to help in choosing the
most effective drug among these agents.
Methods: We performed an indirect comparative effectiveness analysis of the pivotal RCTs of bevacizumab with
interferon, sunitinib, or pazopanib compared to one another or interferon alone in first-line treatment of metastatic or
advanced RCC. Endpoints of interest were overall survival (OS), progression free survival (PFS), and response rate (RR).
Adverse events were also examined.
Results: The meta-estimate of the hazard ratio (95% confidence interval) for OS for bevacizumab with interferon vs.
interferon alone was 0.86 (0.76-0.97), for sunitinib vs. interferon alone was 0.82 (0.67-1.00), for pazopanib vs. interferon alone
was 0.74 (0.57-0.97), for sunitinib vs. bevacizumab with interferon was 0.95 (0.75-1.20), for pazopanib vs. bevacizumab with
interferon was 0.86 (0.64-1.16), and for pazopanib vs. sunitinib was 0.91 (0.76-1.08). Similarly, bevacizumab with interferon,
sunitinib, or pazopanib had better PFS and RR than interferon alone. Sunitinib and pazopanib had better RR than
bevacizumab with interferon and there was suggestive evidence pazopanib may outperform sunitinib in terms of RR.
Conclusions: Bevacizumab with interferon, sunitinib, and pazopanib are adequate first-line options in treatment of
mRCC. Interferon alone should not be considered an optimal first-line treatment.
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Approximately 64,000 new cases of kidney cancer are di-
agnosed each year in the United States and 25%-30% of
these result in death [1]. RCC accounts for 80-90% of
kidney cancers and 70-80% of these are clear cell RCC
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unless otherwise stated.local disease. However, local recurrence or distant me-
tastasis occur in up to 40% of patients treated for local-
ized tumors and 5-year survival is less than 10% in this
subgroup [2-4].
RCC is characterized by a high degree of resistance to
chemotherapy. Historically, tumors have been treated
with cytokines with modest RR and small survival bene-
fit [5]. High-dose interleukin-2 remains an option for
highly selected patients and is associated with durable
remission in a small minority of patients [6,7].
The biology underlying RCC has been elucidated [8].
Mutations in the Von Hippel-Lindau (VHL) gene arel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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inactivated, there is an up-regulation of hypoxia-inducible
factors (HIFs) and subsequent activation of pathways
involved with metabolism, inflammation, and angiogenesis
[9-11]. This rationale has provided a theoretical basis for
the development of several agents targeting angiogenesis,
including vascular endothelial growth factor (VEGF) and
mammalian target of rapamycin (mTOR) [12].
Since 2005 the US Food and Drug Administration
(FDA) and European Medicines Agency (EMA) have
approved novel agents targeting the VEGF-pathway for
patients with mRCC based on large and well-powered
randomized clinical trials. Motzer et al. reported that
sunitinib (an oral VEGF tyrosine kinase inhibitors) im-
proves PFS compared with interferon-alfa [13,14]. Two
studies evaluated the role of bevacizumab (an intraven-
ous antibody against VEGF) in first-line treatment of
mRCC: Rini et al. reported an improvement in PFS and
a trend towards better OS in patients treated with beva-
cizumab plus interferon alfa compared with interferon
alfa alone [15,16] while Escudier et al. (AVOREN trial)
corroborated the results for PFS in the arm treated with
both drugs [17,18]. In addition, Motzer et al. showed
non-inferiority of pazopanib (another oral VEGF tyro-
sine kinase inhibitors) to sunitinib in terms of PFS [19].
Although several agents were successfully developed
and have become the standard of care in treatment of
advanced RCC, the selection of appropriate treatment is
based on clinical setting (previously treated or previ-
ously untreated patients), prognostic stratification (good/
intermediate or poor), and histology [8]. However, there is
little if any comparative data to help choose the most ef-
fective drug to improve patients’ outcomes, and predictive
biomarkers of treatment response are also lacking [20].
We sought to conduct a meta-comparison of pivotal
RCTs in the first-line treatment of metastatic clear cell
RCC in order to establish the most effective therapy in
this setting.
Methods
We performed a meta-comparison of the 4 pivotal RCTs
to evaluate the effectiveness of first-line agents in the
treatment of mRCC in patients with good to intermedi-
ate risk.
Evidence acquisition
A systematic literature search was performed targeting
publications reporting on randomized phase 3 clinical
trials comparing bevacizumab with interferon, sunitinib,
or pazopanib to one another or interferon alone as first-
line therapy for patients with good to intermediate risk
metastatic or advanced renal clear cell carcinoma. Medline
was searched through PubMed using the search phrase
(“sunitinib” OR “bevacizumab” OR “pazopanib”) AND(“renal cell carcinoma” OR “renal-cell carcinoma”) AND
(“advanced” OR “metastatic”) limited to clinical trials dur-
ing the last 10 years. Supplemental searches of the 2014
and 2013 ASCO Annual Meetings and Genitourinary
Cancers Symposiums [21] as well as clinicaltrials.gov [22]
were also performed. Two reviewers independently
screened the titles and abstracts of the identified studies
and the full texts of all potentially relevant studies. Com-
parative estimates from the studies that fulfilled all inclu-
sion criteria were extracted in a standardized form with
disagreements resolved by consensus.
Statistical analysis
Meta-analysis for efficacy outcomes was performed in
the context of linear mixed effects models, with ran-
dom effects for each study and fixed effects for each
study’s specific treatment contrast, based on compara-
tive estimates extracted from each study. Estimates,
confidence intervals, and p-values from analyses strati-
fied by risk factors were used throughout if available.
The linear mixed effects model for meta-analysis is a
generalization of the meta-analysis models proposed in
DerSimonian et al. [23] within which meta-regression
techniques [24,25] can be used to compare treatments
and estimate study-to-study heterogeneity. In particular,
let y ¼ y1 ⋯ yKð Þ0 denote the vector of treatment
contrast estimates (log hazard or odds ratios), let X denote
the design matrix with each row containing the treatment
contrast associated with the particular component of y,
and let W ¼ diag s21;…; s2K
 
denote the diagonal matrix
with the treatment contrast variance estimates. An I2 stat-
istic measuring heterogeneity in treatment contrasts
across studies and having an interpretation similar to
intra-class correlation was developed in a manner simi-
lar to Higgins et al. [26]. In particular, a goodness-of-fit
statistic is calculated as Q = y 'W− 1(I −H)y, where I
denotes a K dimensional identity matrix and H = X
(X 'W− 1X)− 1X 'W− 1 denotes a weighted projection into
the column space of the design matrix X. Under the hy-
pothesis that there is no study-to-study heterogeneity
H0 : σ
2 = 0, Q has a chi-squared distribution χ2K−rank Xð Þ ,
where rank(X) denotes the number of linearly independent
columns in X. The I2 measure of heterogeneity is then the
greater of (Q − (K − rank(X)))/Q and zero. The study-to-
study variability can be estimated by equating the sample
value of Q to its expectation and truncating at zero, giving
σ^ 2 ¼ max Q−trace I−Hf g
trace W −1 I−Hð Þ  ; 0
( )
where trace {A} denotes the sum of the diagonal ele-
ments of A. Then, each estimable meta-estimate is
given by c0β^ , where β^ ¼ X 0W −1 X
 −1
X 0W −1 y and
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, with variance esti-
mate c0 X 0W −1 X
 −1
c . Tests of heterogeneity and I2
can be misleading when treatments differ markedly
even in the presence of study-to-study heterogeneity.
Predictive intervals provide an interval in which a
specific site’s relative efficacy can be expected to fall
and were computed using the study-to-study variance
estimates. Pooling of adverse event rates was performed
separately for each treatment under the assumption of no
study-to-study heterogeneity. All statistical analyses were
performed in R 3.0.1 (R Development Core Team, 2012).
Results
Search results
The search identified 6 publications on 4 studies compar-
ing bevacizumab with interferon, sunitinib, or pazopanib
to one another or interferon alone as first-line treatment in
patients with metastatic or advanced clear cell renal cell
carcinoma. The search is summarized in Figure 1.
The identified studies were Motzer et al. [14] compar-
ing sunitinib to interferon alone, Rini et al. (CALGB
90206) [15,16] and Escudier et al. (AVOREN) [17,18]
comparing bevacizumab with interferon to interferon
alone, and Motzer et al. (COMPARZ) [19] comparing
pazopanib to sunitinib. The most up-to-date reports on
overall survival in the CALGB 90206 and AVORENFigure 1 Selection diagram for studies comparing bevacizumab with
another as first-line therapy for patients with clear cell renal cell carctrials were in Rini et al. [16] and Escudier et al. [18]. All
studies included adult patients with good or intermediate
risk advanced or metastatic renal cell carcinoma with a
clear cell histological component that had not received
prior systemic therapy. Treatment arms, sample size, and
results for included studies are summarized in Table 1.
Overall survival
The test of heterogeneity indicated low study-to-study
variability with Q = 0 on 1 degree of freedom (p = 1) and
I2 = 0%. The overall survival hazard ratio meta-estimate
(95% confidence interval; 95% prediction interval) for
bevacizumab with interferon vs. interferon alone was
0.86 (0.76-0.97; 0.76-0.97), for sunitinib vs. interferon
alone was 0.82 (0.67-1.00; 0.67-1.00), for pazopanib vs.
interferon alone was 0.74 (0.57-0.97; 0.57-0.97), for
sunitinib vs. bevacizumab with interferon was 0.95
(0.75-1.20; 0.75-1.20), for pazopanib vs. bevacizumab
with interferon was 0.86 (0.64-1.16; 0.64-1.16), and for
pazopanib vs. sunitinib was 0.91 (0.76-1.08; 0.76-1.08).
These results are summarized in Table 2 and Figure 2.
Progression free survival
The test of heterogeneity indicated moderate study-to-
study variability with Q = 1.58 on 1 degree of freedom
(p = 0.208) and I2 = 37%. The progression-free survivalinterferon, sunitinib, and pazopanib to interferon alone or one
inoma.
Table 1 Summary of included trials comparing bevacizumab with interferon (Bev + IFN), sunitinib, and pazopanib to
interferon alone (IFN) or one another as first-line therapy for patients with clear cell renal cell carcinoma
Trial Treatment arms (n) Overall survival Progression-free survival Response
Mediana HR (95% CI) Mediana HR (95% CI) Percent OR (95% CI)
Rini et al. (2008; 2013) [15,16] Bev + IFNb,c (n = 369) 18.3 0.86 (0.73-1.01) 8.5 0.71 (0.61-0.83) 26% 2.27 (1.51-3.42)
IFNc (n = 363) 17.4 5.2 13%
Escudier et al. (2007; 2010) [17,18] Bev + IFNb,c (n = 327) 23.3 0.86 (0.72-1.04) 10.2 0.61 (0.51-0.73) 31%f 3.11 (2.04-4.74)
IFNc (n = 322) 21.3 5.4 13%f
Motzer et al. (2013) [19] Pazopanibd (n = 557) 28.4 0.91 (0.76-1.08) 8.4 1.05 (0.90-1.22) 31% 1.35 (1.03-1.75)
Sunitinibe (n = 553) 29.3 9.5 25%
Motzer et al. (2007; 2009) [14] Sunitinibe (n = 375) 26.4 0.82 (0.67-1.00) 11 0.54 (0.45-0.64) 47% 6.33 (4.37-9.15)
IFNc (n = 375) 21.8 5 12%
amonths.
bbevucizumab 10 mg/kg every 2 weeks.
cinterferon alfa 9 million units subcutaneously three times weekly.
dpazopanib 800 mg once daily.
esunitinib 50 mg once daily for 4 weeks, followed by 2 weeks off.
fdenominator for Bev + IFN 306, denominator for IFN + Placebo 289.
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95% prediction interval) for bevacizumab with interferon vs.
interferon alone was 0.66 (0.57-0.77; 0.55-0.81), for sunitinib
vs. interferon alone was 0.54 (0.43-0.67; 0.42-0.69), for pazo-
panib vs. interferon alone was 0.56 (0.42-0.76; 0.41-0.78), for
sunitinib vs. bevacizumab with interferon was 0.81 (0.62-
1.06; 0.61-1.09), for pazopanib vs. bevacizumab with inter-
feron was 0.85 (0.61-1.19; 0.60-1.21), and for pazopanib vs.
sunitinib was 1.05 (0.86-1.28; 0.83-1.33). These results
are summarized in Table 2 and Figure 2.
Response rate
The test of heterogeneity indicated low study-to-study
variability with Q = 1.11 on 1 degree of freedom (p = 0.293)
and I2 = 10%. The response rate odds ratio meta-estimate
(95% confidence interval; 95% prediction interval) for beva-
cizumab with interferon vs. interferon alone was 2.65
(1.94-3.61; 1.89-3.71), for sunitinib vs. interferon alone was
6.33 (4.27-9.37; 4.17-9.59), for pazopanib vs. interferon
alone was 8.51 (5.20-13.93; 5.10-14.19), for sunitinib
vs. bevacizumab with interferon was 2.39 (1.45-3.94;Table 2 Meta-comparisons of bevacizumab with interferon (B
interferon alone (IFN) as first-line therapy for patients with c
Comparison Overall survival
HR (95% CI; 95% PI)
Bev + IFN vs IFN 0.86 (0.76-0.97; 0.76-0.97)
Sun vs IFN 0.82 (0.67-1.00; 0.67-1.00)
Pazo vs IFN 0.74 (0.57-0.97; 0.57-0.97)
Sun vs Bev + IFN 0.95 (0.75-1.20; 0.75-1.20)
Pazo vs Bev + IFN 0.86 (0.64-1.16; 0.64-1.16)
Pazo vs Sun 0.91 (0.76-1.08; 0.76-1.08)1.42-4.01), for pazopanib vs. bevacizumab with inter-
feron was 3.21 (1.79-5.75; 1.77-5.84), and for pazopanib
vs. sunitinib was 1.35 (1.00-1.81; 0.97-1.86). These results
are summarized in Table 2 and Figure 2.
Adverse events
Broadly, adverse event rates were lower for interferon
than for bevacizumab with interferon, sunitinib, or pazo-
panib, while adverse event rates were similar for bevaci-
zumab with interferon, sunitinib, and pazopanib. In
particular, grade 3 or worse adverse events rates (95% con-
fidence intervals) for interferon alone, bevacizumab with
interferon, sunitinib, and pazopanib were 0.544 (0.505-
0.582), 0.705 (0.670-0.738), 0.734 (0.695-0.769), and 0.744
(0.706-0.778), respectively. Adverse event rates are sum-
marized in brief in Table 3 and completely for all reported
adverse events in Additional file 1: Table S1.
Discussion
The treatment of mRCC has evolved over the last 9 years
and the list of first-line targeted therapies is ever increasingev + IFN), sunitinib (Sun), pazopanib (Pazo), and
lear cell renal cell carcinoma
Progression-free survival Response
HR (95% CI; 95% PI) OR (95% CI; 95% PI)
0.66 (0.57-0.77; 0.55-0.81) 2.65 (1.94-3.61; 1.89-3.71)
0.54 (0.43-0.67; 0.42-0.69) 6.33 (4.27-9.37; 4.17-9.59)
0.56 (0.42-0.76; 0.41-0.78) 8.51 (5.20-13.93; 5.10-14.19)
0.81 (0.62-1.06; 0.61-1.09) 2.39 (1.45-3.94; 1.42-4.01)
0.85 (0.61-1.19; 0.60-1.21) 3.21 (1.79-5.75; 1.77-5.84)
1.05 (0.86-1.28; 0.83-1.33) 1.35 (1.00-1.81; 0.97-1.86)
Figure 2 Individual study and comparative meta-estimate hazard ratios and odds ratios for overall survival, progression-free survival,
and response for bevacizumab with interferon (Bev + IFN), sunitinib (Sun), pazopanib (Pazo), and interferon alone (IFN) as first-line
therapy for patients with clear cell renal cell carcinoma.
Haaland et al. BMC Cancer 2014, 14:592 Page 5 of 9
http://www.biomedcentral.com/1471-2407/14/592[20]. Sunitinib, pazopanib, and bevacizumab plus inter-
feron have demonstrated convincing clinical benefit in pa-
tients with favorable or intermediate prognosis [13-19,27].
These new interventions have been evaluated, compared to
interferon or one another as first-line treatment but there
are limited phase 3 trials providing data comparing differ-
ent treatments.
At present, the selection of appropriate treatment
is based on prognostic risk category, available PFS
and OS data, and toxicity profile. The most widely
used prognostic tool is the Memorial Sloan Kettering
Cancer Center (MSKCC) model, which stratifies progno-
sis as good, intermediate or poor, based on high lactate
dehydrogenase, low Karnofsky score, high corrected cal-
cium, low hemoglobin and shorter time from diagnosis
to treatment [28,29]. In the era of targeted therapy, the
International mRCC Database Consortium (IMDC) prog-
nostic model has been used to stratify patients according
to the presence of six adverse prognostic factors: Kar-
nofsky score <80%, low hemoglobin, time from diagnosis
to treatment of <1 year, high corrected calcium, throm-
bocytosis, and neutrophilia [8,20]. In addition, histology
(clear cell vs. non-clear cell), personal experience and
cost are also important considerations in the decision-
making process [30].The intent of our study was to perform meta-
comparison of the pivotal RCTs to provide evidence on
the best first-line treatment of patients with good to inter-
mediate risk mRCC. OS, PFS, and RR favored the use
of bevacizumab with interferon, sunitinib, or pazopanib
when compared to interferon alone. There was evidence
that sunitinib and pazopanib outperformed bevacizumab
with interferon in terms of RR, while there was suggestive
evidence that RR may be better with pazopanib than suni-
tinib. While there was a low to moderate heterogeneity
across studies in efficacy endpoints, comparative results
should be interpreted cautiously.
A number of related studies did not meet inclusion
criteria, but were also of interest. Sternberg et al. dem-
onstrated the efficacy of pazopanib as compared to pla-
cebo in PFS improvement [31,32]. Hutson et al. failed to
show a statistically significant PFS benefit for axitinib over
sorefenib as first-line treatment in patients with mRCC
[33]. Randomized trials showed superiority of sorafenib
over placebo in second-line therapy in a phase 3 trial, but
not over interferon as first-line therapy in a phase 2 trial
[34,35]. Several older studies, MRCRCC [36], Kriegmair
et al. [37], Pyrhonen et al. [38], and Steineck et al. [39],
provided evidence largely favoring interferon over con-
trols. These studies were not incorporated in the present
Table 3 Adverse event rates by approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the
treatment of good and intermediate risk metastatic clear cell renal cell carcinoma
Interferon Bevacizumab with interferon Sunitinib Pazopanib
Rate (95% CI) Rate (95% CI) Rate (95% CI) Rate (95% CI)
Any grade 3, 4, or 5 0.544 (0.505-0.582) 0.705 (0.670-0.738) 0.734 (0.695-0.769) 0.744 (0.706-0.778)
AE leading to discontinuation of drug 0.185 (0.158-0.217) 0.282 (0.237-0.332) 0.197 (0.173-0.224) 0.244 (0.210-0.281)
AE leading to death 0.013 (0.008-0.022) 0.016 (0.009-0.028) 0.022 (0.014-0.033) 0.023 (0.014-0.040)
Thrombocytopenia 0.135 (0.115-0.157) 0.084 (0.066-0.107) 0.732 (0.703-0.760) 0.410 (0.370-0.451)
Grade≥ 3 0.009 (0.005-0.017) 0.021 (0.013-0.035) 0.164 (0.141-0.189) 0.036 (0.023-0.055)
Neutropenia 0.320 (0.292-0.350) 0.260 (0.229-0.294) 0.714 (0.684-0.742) 0.366 (0.327-0.407)
Grade≥ 3 0.069 (0.055-0.087) 0.069 (0.052-0.090) 0.192 (0.168-0.218) 0.045 (0.031-0.066)
Anemia 0.365 (0.336-0.395) 0.132 (0.109-0.159) 0.674 (0.643-0.703) 0.309 (0.272-0.348)
Grade≥ 3 0.051 (0.039-0.067) 0.033 (0.022-0.049) 0.076 (0.060-0.095) 0.022 (0.012-0.037)
Asthenic conditions or fatigue 0.576 (0.545-0.606) 0.638 (0.602-0.673) 0.593 (0.561-0.624) 0.545 (0.503-0.586)
Grade≥ 3 0.178 (0.156-0.203) 0.250 (0.220-0.284) 0.146 (0.125-0.171) 0.106 (0.083-0.135)
Diarrhea 0.152 (0.127-0.181) 0.205 (0.165-0.251) 0.589 (0.557-0.621) 0.628 (0.587-0.667)
Grade≥ 3 0.011 (0.005-0.022) 0.021 (0.010-0.042) 0.082 (0.066-0.102) 0.088 (0.068-0.115)
Nausea 0.467 (0.430-0.504) 0.580 (0.529-0.630) 0.482 (0.450-0.514) 0.446 (0.405-0.487)
Grade≥ 3 0.030 (0.020-0.045) 0.072 (0.049-0.103) 0.034 (0.024-0.047) 0.022 (0.012-0.037)
Anorexia or appetite loss 0.402 (0.372-0.432) 0.542 (0.505-0.579) 0.358 (0.327-0.389) 0.374 (0.334-0.415)
Grade≥ 3 0.043 (0.032-0.057) 0.104 (0.084-0.129) 0.029 (0.020-0.042) 0.014 (0.007-0.028)
HTN 0.054 (0.042-0.070) 0.273 (0.242-0.307) 0.364 (0.334-0.396) 0.464 (0.423-0.506)
Grade≥ 3 0.006 (0.003-0.013) 0.072 (0.055-0.093) 0.137 (0.116-0.160) 0.148 (0.121-0.180)
Proteinuria 0.049 (0.035-0.069) 0.452 (0.416-0.489) 0.137 (0.111-0.168) 0.177 (0.147-0.211)
Grade≥ 3 0.002 (0.000-0.009) 0.112 (0.090-0.137) 0.040 (0.027-0.060) 0.042 (0.028-0.062)
Pyrexia 0.386 (0.349-0.423) 0.451 (0.399-0.504) 0.128 (0.108-0.151) 0.087 (0.066-0.113)
Grade≥ 3 0.009 (0.004-0.020) 0.024 (0.012-0.046) 0.011 (0.006-0.020) 0.004 (0.001-0.013)
Headache 0.161 (0.135-0.191) 0.234 (0.192-0.282) 0.186 (0.163-0.213) 0.227 (0.194-0.264)
Grade≥ 3 0.006 (0.002-0.015) 0.021 (0.010-0.042) 0.011 (0.006-0.020) 0.027 (0.016-0.044)
Thyroid dysfunction 0.010 (0.005-0.020) 0.006 (0.002-0.020) 0.202 (0.177-0.229) 0.121 (0.096-0.151)
Grade≥ 3 0.006 (0.002-0.014) 0.006 (0.002-0.020) 0.011 (0.006-0.020) 0.000 (0.000-0.007)
Weight loss 0.130 (0.107-0.157) 0.157 (0.124-0.199) 0.085 (0.068-0.104) 0.152 (0.124-0.184)
Grade≥ 3 0.013 (0.007-0.024) 0.041 (0.025-0.067) 0.005 (0.002-0.013) 0.009 (0.004-0.021)
Dyspnea 0.098 (0.081-0.118) 0.139 (0.115-0.166) 0.143 (0.122-0.167) 0.137 (0.111-0.168)
Grade≥ 3 0.026 (0.018-0.037) 0.036 (0.024-0.052) 0.023 (0.015-0.035) 0.025 (0.015-0.042)
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potential for bias in the present day context as continual
advances in supportive care may have altered the relative
effectiveness of treatments.
Initially, phase 2 studies and studies comparing one of
the treatments of interest to a control were considered
for the present comparison. The broader search identi-
fied two additional studies, the phase 2 TORAVA study
comparing temsirolimus and bevacizumab, sunitinib,
and bevacizumab with interferon [40] and the phase 3
Sternberg et al. study comparing pazopanib to placebo
[31,32]. However, the TORAVA study did not reporthazard ratios for overall or progression-free survival
and contained 12% poor risk patients. The Sternberg
et al. study, on the other hand, did not add information on
the comparative effectiveness of bevacizumab with inter-
feron, sunitinib, and pazopanib, as it was the only relatively
recent study that compared an agent of interest to control.
A meta-analysis of seven RCTs that evaluated suniti-
nib, bevacizumab with interferon, or sorafenib compared
with interferon or placebo showed that anti-VEGF agents
significantly prolonged PFS and offered important clinical
benefits to patients with mRCC. Among these drugs, suni-
tinib had higher RR [41]. Interestingly, Mills and colleagues
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and 2 abstracts that evaluate these same drugs. Using inter-
feron as the control arm, they showed that sunitinib was
superior to both sorafenib (HR 0.58, 95% CI, 0.38–0.86,
p < 0.001) and bevacizumab with interferon (HR 0.75,
95% CI, 0.60–0.93, p = 0.001). Sorafenib was not statisti-
cally different from bevacizumab with interferon [42].
However, both of these studies included phase 2 and
second-line studies, as well as studies on drugs not com-
monly used in patients with good to intermediate risk.
The PISCES study compared patient preference for
pazopanib and sunitinib as first-line treatment of mRCC
in the context of a randomized crossover trial, and found
that 70% of patients preferred treatment with pazopanib
because of reductions in fatigue and improved quality
of life [43]. In addition, Cella and colleagues reported
quality-of-life in favor of pazopanib over sunitinib in the
COMPARZ study [44]. We found that adverse event
rates were lower for interferon than for bevacizumab
with interferon, sunitinib, or pazopanib, while adverse
event rates were similar for bevacizumab with interferon,
sunitinib, and pazopanib.
Tolerability is an important consideration in selecting
therapy for mRCC with increasing patient survival and
long-term use of therapy [45]. A recent meta-analysis
demonstrated that bevacizumab is asscociated with an
increase of 33% in fatal adverse events compared with
chemotherapy alone [46]. Furthermore, Schutz et al.
reported that use of VEGF tyrosine kinase inhibitors was
associated with increased risk of fatal adverse events [47].
Patient comorbidities are also important considerations in
treatment selection.
Novel agents for advanced RCC require selection para-
digms to optimize first-line therapy. Recently, Choueiri
and colleagues evaluated several potential biomarkers
along the VHL/HIF1α/HIF2α axis and none of them
were found predictive of pazopanib activity [48]. Cur-
rently, there are no clinical factors or biomarkers that
can reliably predict which targeted therapies patients will
respond to.
Our study has limitations. Direct comparisons remain
the highest level of evidence of therapeutic effectiveness
and our results must be interpreted with caution since
several are based on indirect comparison. Further, des-
pite the fact that all selected RCTs were of high quality,
agents were evaluated in slightly different clinical set-
tings and populations. In addition, all other factors
equals, individual patient data (IPD) meta-analyses are
preferable to aggregated data meta-analyses because IPD
allows for subgroup analyses, inclusion of inappropriately
excluded patients, data checking, randomization checking,
verification of analyses, and potentially more long-term
and uniform follow-up [49]. However, in the current
context, the main results are not likely to be alteredmeaningfully by using IPD, as all included efficacy data is
intention-to-treat, based on simple and standard analyses,
and all included studies are relatively high-quality in terms
of trial execution and outcomes assessment.
Conclusions
In summary, several studies support VEGF-targeted ther-
apies as the standard of mRCC treatment. Our analysis
provides a comparison on the basis of the pivotal RCTs
and demonstrates that any of bevacizumab with interferon,
sunitinib, and pazopanib offer improved survival and sub-
stantial clinical benefits in comparison with interferon
alone. Efforts to identify predictive biomarkers for treat-
ment response and direct comparisons among the drugs
are needed to customize therapy in mRCC.
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